Founded in 1994, Beijing BGI-GBI Biotech Co., Ltd.(GBI) is the core subsidiary of BGI Group which is one
of the largest genomic organizations in the world. GBI mainly focuses on the business including R&D,
manufacture and sales of In Vitro Diagnostic (IVD) kits and clinical lab services. GBI is among the first batch
of IVD enterprises who have obtained GMP certificate in China. All the blood-screening products have
100% passed inter-batch inspection of National Medical Product Administration(NMPA) for over 20 years
in a row, and GBI has repeatedly ranked first with full marks in clinical quality assessment organized by the
National Center for Disease Control and Prevention(NCDCP).
To improve people's health, we innovate medical detection model and enhance the efficiency of diagnosis
and treatment. GBI is one of IVD enterprises which possesses the most comprehensive platforms. So far
GBI has established methodological platforms such as mass spectrometry, nucleic acid testing, ELISA,
CLIA, CMIA, POCT, gene sequencing and so on covering fields like reproductive health, cancer screening
and medication, regular diseases, infectious diseases, blood screening, and nutrition detection. We
have independently developed more than 100 categories of diagnostic kits approved by NMPA and have
obtained EU-CE Markings for most products. In 2018, GBI undertook National S&T Major Project of China
and One Belt One Road national research task. We have deep cooperation with hospitals in China, and we
are also one of the largest reagent suppliers of large-scale physical examinations and healthcare centers.
Not only have we focused on people's livelihood for a long run, GBI has also played an important role in
providing aids against major disasters such as SARS, H1N1, and COVID-19.
